A new High-Resolution Imaging System (HiRIS2) detector for preclinical SPECT imaging

Massari, R.; D’Elia, Annunziata; Soluri, A.

doi:10.1016/j.nima.2018.11.095

Cited by 7 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The spatial resolution of clinical SPECT is 5–10 mm (Dewaraja et al 2012). Recently resolutions of 2.5 and 1.6 mm were reported in images of a phantom using a multi-pinhole clinical (Chen et al 2018) or preclinical (Massari et al 2019) SPECT system, respectively. However, for animal studies, it is possible to perform autoradiography in combination with immunohistochemical staining of excised tissues ex vivo to understand the heterogeneous radioactivity distribution in different regions of tumours and normal organs (Lee et al 2010).…”

Section: Dosimetric Propertiesmentioning

confidence: 99%

Auger electrons for cancer therapy – a review

Facca

Cai

et al. 2019

EJNMMI radiopharm. chem.

260

207

View full text Add to dashboard Cite

Background: Auger electrons (AEs) are very low energy electrons that are emitted by radionuclides that decay by electron capture (e.g. 111 In, 67 Ga, 99m Tc, 195m Pt, 125 I and 123 I). This energy is deposited over nanometre-micrometre distances, resulting in high linear energy transfer (LET) that is potent for causing lethal damage in cancer cells. Thus, AE-emitting radiotherapeutic agents have great potential for treatment of cancer. In this review, we describe the radiobiological properties of AEs, their radiation dosimetry, radiolabelling methods, and preclinical and clinical studies that have been performed to investigate AEs for cancer treatment. Results: AEs are most lethal to cancer cells when emitted near the cell nucleus and especially when incorporated into DNA (e.g. 125 I-IUdR). AEs cause DNA damage both directly and indirectly via water radiolysis. AEs can also kill targeted cancer cells by damaging the cell membrane, and kill non-targeted cells through a cross-dose or bystander effect. The radiation dosimetry of AEs considers both organ doses and cellular doses. The Medical Internal Radiation Dose (MIRD) schema may be applied. Radiolabelling methods for complexing AE-emitters to biomolecules (antibodies and peptides) and nanoparticles include radioiodination (125 I and 123 I) or radiometal chelation (111 In, 67 Ga, 99m Tc). Cancer cells exposed in vitro to AE-emitting radiotherapeutic agents exhibit decreased clonogenic survival correlated at least in part with unrepaired DNA double-strand breaks (DSBs) detected by immunofluorescence for γH2AX, and chromosomal aberrations. Preclinical studies of AE-emitting radiotherapeutic agents have shown strong tumour growth inhibition in vivo in tumour xenograft mouse models. Minimal normal tissue toxicity was found due to the restricted toxicity of AEs mostly on tumour cells targeted by the radiotherapeutic agents. Clinical studies of AEs for cancer treatment have been limited but some encouraging results were obtained in early studies using 111 In-DTPAoctreotide and 125 I-IUdR, in which tumour remissions were achieved in several patients at administered amounts that caused low normal tissue toxicity, as well as promising improvements in the survival of glioblastoma patients with 125 I-mAb 425, with minimal normal tissue toxicity. Conclusions: Proof-of-principle for AE radiotherapy of cancer has been shown preclinically, and clinically in a limited number of studies. The recent introduction of many biologically-targeted therapies for cancer creates new opportunities to design novel AE-emitting agents for cancer treatment. Pierre Auger did not conceive of the application of AEs for targeted cancer treatment, but this is a tremendously exciting future that we and many other scientists in this field envision.

show abstract

Section: Dosimetric Propertiesmentioning

confidence: 99%

Auger electrons for cancer therapy – a review

Facca

Cai

et al. 2019

EJNMMI radiopharm. chem.

260

207

View full text Add to dashboard Cite

show abstract

“…The preclinical SPECT scanner presented in this work has been designed on the basis of an imaging system previously engineered by our group 5 . The detectors, named High-Resolution Imaging System (HiRIS2), have been developed using several Monte Carlo (MC) simulations to de ne the mechanical structure and compose the preparatory technical drawings 8 .…”

Section: Methodsmentioning

confidence: 99%

“…In this context, the need to develop imaging systems able to precisely visualize small details has arisen. Our research group has previously developed high-performance scintigraphic detectors for small animal imaging 5,6 . The feasibility of our patented method named Super Spatial Resolution (SSR) 7 has been simulated for its application on a scintigraphic system giving as a result planar or three-dimensional (3D) images with a resolution enhancement 8 .…”

Section: Introductionmentioning

confidence: 99%

Development of a high-resolution SSR-SPECT system for preclinical imaging and neuroimaging

D’Elia

Soluri

Galli

et al. 2022

Nuclear Instruments and Methods in Physics Research Section A:

View full text Add to dashboard Cite

The utility of animal models in preclinical research has been increasing by the availability of methods for in vivo imaging. In particular, techniques like single photon emission computed tomography (SPECT) show high potential, which is usually limited by spatial resolution. This represents an important parameter in uencing scanner design, given the small size of the anatomical structures to be investigated. The purpose of the present work was to assess the performance of a scintigraphic system with improved spatial resolution based on our previous detector by applying the Super Spatial Resolution (SSR). Our dual-head SPECT system is composed of gamma cameras based on the Hamamatsu H13700 position-sensitive photomultiplier tube (PSPMT). In each detector head, the PSPMT is coupled to a 28×28 array of CRY018 scintillation crystals. The pure Tungsten parallel square hole collimator ensures the position sensitivity, and a dedicated resistive chain readout so as an ADC board have been proprietary designed.To nalize the mechanical development of the SSR-SPECT system several tests were carried out. Based on the results obtained in the test phase, a partial review of the mechanical design was performed. Then a dedicated machine handling software was developed, and in particular, a kinematic software debugging and testing was assessed. Finally, several experiments were carried out by using Derenzo phantoms and capillaries lled with radioactive sources. Finally, the performance of our system was evaluated performing small animal imaging studies.The SPECT spatial resolution was experimentally determined to be about 1.6 mm. We reach a resolution of 1.18 mm by applying the SSR based on two images.The results of this study demonstrated the good capability of the system as a suitable tool for preclinical imaging especially in elds like neuroscience for the study of small brain structures.

show abstract

“…The characterization of the sole HiRIS2 detector has been performed in our previous work by using complex patterns allowing the assessment of the spatial linearity and the overall imaging capability 5,6 . In this study, the HiRIS2 SPECT system performance was determined experimentally using a customdesigned polymethyl methacrylate (PMMA) phantom, and a glass capillary, both lled with a solution of 99m TcO 4 -( -ray 140.5 keV).…”

Section: Phantoms Evaluationmentioning

confidence: 99%

Development of a High-resolution SSR-SPECT System for Preclinical Imaging and Neuroimaging

D’Elia

Soluri

Galli

et al. 2021

Preprint

View full text Add to dashboard Cite

The utility of animal models in preclinical research has been increasing by the availability of methods for in vivo imaging. In particular, techniques like single photon emission computed tomography (SPECT) show high potential, which is usually limited by spatial resolution. This represents an important parameter influencing scanner design, given the small size of the anatomical structures to be investigated. The purpose of the present work was to assess the performance of a scintigraphic system with improved spatial resolution based on our previous detector by applying the Super Spatial Resolution (SSR). Our dual-head SPECT system is composed of gamma cameras based on the Hamamatsu H13700 position-sensitive photomultiplier tube (PSPMT). In each detector head, the PSPMT is coupled to a 28×28 array of CRY018 scintillation crystals. The pure Tungsten parallel square hole collimator ensures the position sensitivity, and a dedicated resistive chain readout so as an ADC board have been proprietary designed. To finalize the mechanical development of the SSR-SPECT system several tests were carried out. Based on the results obtained in the test phase, a partial review of the mechanical design was performed. Then a dedicated machine handling software was developed, and in particular, a kinematic software debugging and testing was assessed. Finally, several experiments were carried out by using Derenzo phantoms and capillaries filled with radioactive sources. Finally, the performance of our system was evaluated performing small animal imaging studies. The SPECT spatial resolution was experimentally determined to be about 1.6 mm. We reach a resolution of 1.18 mm by applying the SSR based on two images. The results of this study demonstrated the good capability of the system as a suitable tool for preclinical imaging especially in fields like neuroscience for the study of small brain structures.

show abstract

A new High-Resolution Imaging System (HiRIS2) detector for preclinical SPECT imaging

Cited by 7 publications

References 14 publications

Auger electrons for cancer therapy – a review

Auger electrons for cancer therapy – a review

Development of a high-resolution SSR-SPECT system for preclinical imaging and neuroimaging

Development of a High-resolution SSR-SPECT System for Preclinical Imaging and Neuroimaging

Contact Info

Product

Resources

About